Evaluation of the safety and effectiveness of switching from standard to extended interval dosing for durvalumab in unresectable stage III non-small cell lung cancer.

e20501Background: In 2018, the FDA approved durvalumab with weight-based dosing of 10 mg/kg every 2 weeks for unresectable, Stage III non-small cell lung cancer (NSCLC) following chemoradiation the...